Characteristics and Trends of Serratia Blood Stream Infections

Hatem Elabd¹, MD, Anjuli Eagleston¹, MD, Dominique Brandt², MA, MS, Stephen Blatt¹, MD FACP

¹TriHealth Department of Internal Medicine and Infectious Diseases, ²TriHealth Hatton Research Institute

BACKGROUND

- Serratia is an opportunistic pathogen.
- Causes an array of infections : UTIs, pneumonia, wound infections, skin and soft tissue infections, surgical site infections and although rare, endocarditis and bacteremia.


RATIONALE

To identify the characteristics of patients with community-acquired *Serratia* blood stream infections within the TriHealth, Cincinnati (OHIO) inpatient population.

METHODS

- Retrospective cohort study of patients admitted to 2 community hospitals, from 01-01-2014 to 12-31-2018.
- Inclusion: positive blood culture for or Serratia species.

RESULTS



RESULTS

DATIENT CUADACTERISTICS AT ADMISSION		
PATIENT CHARACTERISTICS AT ADMISSION	SERRATIA (n=103)	
Age, Median (IQR)	56.8 (41.4-72)	
Female, n (%)	40 (38.8%)	
RACE, N (%)		
Black	12 (11.6%)	
White	88 (85.4%)	
Other	3 (2.9%)	
COMORBIDITIES, N (%)		
Congestive heart failure	12 (11.6%)	
Chronic obstructive pulmonary disease	10 (9.7%)	
End-Stage Renal Disease	8 (7.8%)	
Liver Cirhosis	9 (8.7%)	
Chronic kidney disease	13 (12.6%)	
Diabetes Mellitus	26 (25.2%)	
hepatitis C virus infection	40 (39.6%)	
Immuno supression*	20 (19.8%)	
Surgical procedure < 30 days*	13 (12.6%)	
Instrumentation of GU** or Respiratory Tract < 30 day	2 (1.9%)	
Indwelling Catheter	32 (31.1%)	
LIVING SITUATION, N (%)		
Long Term Care Facility or Hospital	20 (19.4%)	
Home	79 (76.7%)	
Jail	1 (0.97%)	
Homeless	3 (2.9%)	
LABORATORY RESULTS, N (%)		
Serratia Species, n (%)		
Serratia Liquefaciens	3 (2.9%)	
Serratia Marcescens	94 (91.3%)	
Serratia Odorifera	2 (1.9%)	
Serratia Plymuthica	4 (3.9%)	
Extended spectrum beta-lactamase (ESBL)*, n (%)		
Possible	26 (25.2%)	
Confirmed	11 (10.7%)	
Resistance to 3rd generation Cephalosporine, n (%)	15 (14.6%)	
Other organisms in blood culture, n (%)	9 (8.3%)	
SOURCE OF CONTAMINATION, N (%)		
Non IV Drug Users	61 (59.2%)	
Urine	13 (21.3%)	
Lung	2 (3.3%)	
Intra abdominal	4 (6.6%)	
Skin/soft tissue	10 (16.4%)	
Indwelling Catheter	29 (47.5%)	
History of IV drug use	42 (40.8%)	
PATIENT TREATMENT, N (%)	· · · · · · ·	
Antibiotics use at admission	98 (95.1%)	
* n=101, GU** genitourinary tract	50 (55.170)	
n-101, 00 genitounnury truct		

RESULTS

PATIENT OUTCOMES	IV DRUG USERS	NON-IV DRUG USERS	P-value	
	N = 42	N = 61	r-value	
Complications, n (%)	22 (52.4%)	5 (8.2%)	<.000	
Additional bacteremia	7 (16.7%)	1 (1.6 %)	0.01	
Septic shock (requiring vasopressor), n (%)	6 (14.3%)	4 (6.6%)	0.16	
ICU admission, n (%)	10 (23.8%)	9 (14.8%)	0.18	
Length of Stay in days, median (IQR)	8 (2.75-11.25)	6 (4-16)	0.59	
In-hospital mortality, n (%)				
Due to Serratia	0	0		
Other causes	0	2 (3.3%)		
30-day mortality, n (%)				
Due to Serratia	0	0		
Other causes	2 (4.8%)	0		
90-day mortality, n (%)				
Due to Serratia	0	0		
Other causes	1 (2.4%)	1 (1.6%)		
90-day readmission, n (%)				
Due to Serratia	0	0		
Other causes	10 (23.8%)	12 (19.7%)		
Recurrence of Serratia infection*, n (%)	3 (7.1%)	3 (4.9%)	0.47	

• IV drug users (42%) with Serratia bacteremia are at higher risk for

complications (52.4% vs. 8.2%, p < .0001) and have additional bacteremia (16.7% vs. 1.6%, p=0.018).

• 30- and 90-day mortality is not related to Serratia bacteremia.

CONCLUSIONS

- A significant proportion of patients hospitalized with Serratia bacteremia are injecting drug users (40%) and they frequently have hepatitis C coinfection.
- Patients with Serratia bacteremia have a high readmission rate and a prolonged length of stay.
- A significant proportion of patients with Serratia bacteremia have possible or confirmed ESBL producing isolates suggesting that Carbapenem antibiotic therapy may be appropriate for empiric treatment in this group of patients.